



HW

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)


		Application Number	10/750,262
		Filing Date	December 31, 2003
		First Named Inventor	Daniel E. AFAR
		Art Unit	N/A
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	7	Attorney Docket Number	511582001611

ENCLOSURES (Check all that apply)


<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Form 1449, 3 pages Return Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement, 3 pages	<input type="checkbox"/> CD, Number of CD(s)	
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		

CUSTOMER NO. 25225

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	MORRISON & FOERSTER LLP Kate H. Murashige - 29,959
Signature	
Date	6/15/04

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.


Dated: 6-15-04 Signature:  (Rhea Amid)



PATENT
Docket No. 511582001611

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on June 15, 2004.


Rhea Amid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Daniel E. H. AFAR et al.

Serial No.: 10/750,262

Filing Date: December 31, 2003

For: SERPENTINE TRANSMEMBRANE
ANTIGENS EXPRESSED IN HUMAN
CANCERS AND USES THEREOF

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 10/011,095, filed December 6, 2001, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - A fee is required. A check in the amount of __ is enclosed.
 - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **511582001611**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: June 15, 2004

Respectfully submitted,

By: Kate H. Murashige
Kate H. Murashige
Registration No. 29,959

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125

<p>Form PTO-1449</p> <p>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</p> <p>(Use several sheets if necessary)</p> <p>O I P E JUN 1 8 2004 JC151 PATENT & TRADEMARK OFFICE</p>	Docket Number 511582001611		Application Number 10/750,262	
	Applicant		Daniel E. H. AFAR et al.	
	Filing Date December 31, 2003		Group Art Unit To Be Assigned	
	Mailing Date June 15, 2004			

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	12/2001	6,329,503	Afar et al.	530	350	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	2.	04/1998	EP 0 834 563	Europe			
	3.	04/1994	WO 94/09150	WIPO			
	4.	05/1998	WO 98/18489	WIPO			
	5.	08/1998	WO 98/37093	WIPO			
	6.	08/1998	WO 98/37418	WIPO			
	7.	11/1998	WO 98/53071	WIPO			
	8.	02/1999	WO 99/06548	WIPO			
	9.	02/1999	WO 99/06550	WIPO			
	10.	02/1999	WO 99/61469	WIPO			
	11.	12/1999	WO 99/62941	WIPO			
	12.	01/2000	WO 00/04149	WIPO			
	13.	02/2000	WO 00/35937	WIPO			
	14.	02/2001	WO 01/12662	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	15.	Haverstick et al., Cancer Research (2000) pp. 1002-1008
	16.	Diss et al., FEBS Letters (1998) 427:5-10
	17.	Grimes and Djamgoz, Journal of Cellular Physiology (1998) 175:50-58
	18.	Skryma et al., The Prostate (1997) 33:112-122

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 511582001611	Application Number 10/750,262
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant	Daniel E. H. AFAR et al.
		Filing Date December 31, 2003	Group Art Unit To Be Assigned
		Mailing Date June 15, 2004	

19.	Gutierrez et al., Journal of Physiology (1999) 517.1:95-107
20.	Lepple-Wienhues et al., J. Membrane Biol. (1996) 151:149-157
21.	Marino et al., Tumor Biol. (1994) 15:82-89
22.	Pancrazio et al., Cancer Research (1989) 49:5901-5906
23.	Nie et al., Cell Calcium (1997) 22(2):75-82
24.	Database EMBL Nucleotide and Protein Sequences, August 25, 1996, XP002128081, AA032221, Hinxton, GB
25.	Database EMBL Nucleotide and Protein Sequences, May 1, 1999, XP002128083, O95034 (clone RG041D11), Hinxton, GB
26.	Database EMBL Nucleotide and Protein Sequences, June 15, 1998, XP002128084, AC004969 (clone DJ1121E10), Hinxton, GB
27.	Database EMBL Nucleotide and Protein Sequences, May 13, 1997, XP002128082, AC002064, Hinxton, GB
28.	Abu-Threideh et al., EMBL/GENBANK/DDBJ DATABASES, June 1998
29.	Abu-Threidah et al., GENBANK, (Accession No. 095034), National Library of Medicine, Bethesda MD, May 1, 1999
30.	Herbert et al., The Dictionary of Immunology, Academic Press, 4th edition, 1995
31.	Greenspan et al., Nature Biotechnology (1999) 7:936-937
32.	Duclert et al., GENBANK, (Accession No. Y11840), National Library of Medicine, Bethesda MD, February 11, 1999
33.	Cate et al., GENBANK, (Accession No. W86309), National Library of Medicine, Bethesda MD, November 1998
34.	Gura, Science (1997) 278:1041-1042
35.	Spitler, Cancer Biotherapy (1995) 10:1-3
36.	Lal et al., US Patent No. 6,048,970, May 1998, USPTO database sequence listing
37.	Bellone et al., Immunology Today (1999) 20(10):457-462
38.	Alberts et al., Molecular Biology of the Cell, 3rd edition, 1994, p.465
39.	Shantz and Pegg, Int. J. of Biochem. and Cell Biol. (1999) 31:107-122
40.	McClean and Hill, Eur. J. of Cancer (1993) 29:2243-2248
41.	Fu et al., EMBO Journal (1996) 15:4392-4401
42.	Database EMBL "Human BAC clone CTB-167B5 from 7q21, complete sequence," June 17, 1998, XP002173859 (Accession AC 003991 Waterstone, R.)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

<p>Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i></p>	Docket Number 511582001611	Application Number 10/750,262
	Applicant Daniel E. H. AFAR et al.	
	Filing Date December 31, 2003	Group Art Unit To Be Assigned
	Mailing Date June 15, 2004	

43.	Hubert et al., PNAS USA (1999) 96(25):14523-14528
44.	Burgess et al., Jnl. Cell Bio. (1990) 111:2129-2138
45.	Lazar et al., Mol. Cell Bio. (1988) 8(3):1247-1252
46.	Bowie et al., Science (1990) 247:1306-1310
47.	Rieger et al., Glossary of Genetics and Cytogenetics, Springer-Verlag 1976, p. 17
48.	International Search Report mailed on May 11, 2004, for PCT patent application no. PCT/US03/18661 filed on June 11, 2003, 3 pages.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
PTO/SB/ 08 (2-92) sd- 203485	Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE